Fexuprazan offers superior gastritis relief in two weeks compared to Rebamipide

Gastritis is a common ailment, treated with either the novel drug Fexuprazan or the widely used Rebamipide. A recent study published in the “World Journal of Clinical Cases” compared their effectiveness for the treatment of acute and chronic gastritis. Researchers compared data from a phase III trial of Fexuprazan (10 mg, twice a day) with data from two studies of Rebamipide (100 mg thrice a day).

They assessed erosion improvement and healing rates after two weeks of Fexuprazan versus two or four weeks of Rebamipide, calculating risk differences and confidence intervals for treatment effects. In the primary analysis, Fexuprazan showed better erosion improvement and healing rates than Rebamipide. In the additional analysis, Fexuprazan's results were similar to four weeks of Rebamipide (Table 1).

Thus, the study concluded that Fexuprazan provides quicker relief than Rebamipide over two weeks. It offers comparable results to a four-week course of Rebamipide, making it a more efficient choice for gastritis treatment.